Seegene

Seegene Acquisitions (Net)

The Acquisitions (Net) of Seegene (096530.KQ) as of Nov 19, 2026 is 78.30 B KRW. In the previous year, Acquisitions (Net) was -246.45 B KRW — a change of -131.77% (higher).

Acquisitions (Net)

78.30 BKRW

YoY

-131.77%

Last updated:

Acquisitions (Net) of Seegene is 2024 78.30 B KRW. Acquisitions (Net) of Seegene was 2023 -246.45 B KRW. It decreases by -131.77% higher compared to the previous year.

The Seegene Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
12.38 B KRW
Jan 1, 2018
4.92 B KRW
Jan 1, 2019
-2.13 B KRW
Jan 1, 2020
-17.40 B KRW
Jan 1, 2021
-36.56 B KRW
Jan 1, 2022
-31.53 B KRW
Jan 1, 2023
-246.45 B KRW
Jan 1, 2024
78.30 B KRW
The Seegene Acquisitions (Net) history
YEARAcquisitions (Net)YoY
78.30 BKRW-131.77%
-246.45 BKRW+681.67%
-31.53 BKRW-13.77%
-36.56 BKRW+110.07%
-17.40 BKRW+717.86%
-2.13 BKRW-143.22%
4.92 BKRW-60.22%
12.38 BKRW+1,276.86%
899.00 MKRW-105.05%
-17.81 BKRW+478.38%
-3.08 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Acquisitions (Net) of Seegene is 78.30 B KRW in 2024.

Acquisitions (Net) of Seegene changed from -246.45 B KRW to 78.30 B KRW, representing a -131.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Seegene since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Seegene

All Key Metrics — Seegene